High-dose Glucocorticoid for the Treatment of Myeloid Sarcoma
Faculty of Medicine, Department of pediatric Hematology, Hacettepe University, Ankara 06100, Turkey
- *Corresponding Author:
- Gonul Hicsonmez, M.D
Department of pediatric Hematology
Hacettepe University, Erdemkent Sitesi
Ardic Sok. No.19, UmitkOy, Ankara 06000, Turkey
E-mail: [email protected]
Received date February 21, 2013; Accepted date March 26, 2013; Published date March 28, 2013
Citation: Hicsonmez G (2013) High-dose Glucocorticoid for the Treatment of Myeloid Sarcoma. J Leuk (Los Angel) 1:103. doi: 10.4172/2329-6917.1000103
Copyright: ©2013 Hicsonmez G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Myeloid sarcoma is a tumor of myeloblast or poorly differentiated myeloid cells that can occur in extramedullary sites, as isolated tumor, concomitantly with or after the diagnosis of acute myeloblastic leukemia. Despite considerable improvement achieved in the outcome of patients with acute myeloblastic leukemia by using intensive chemotherapy and/or hematopoietic stem cell transplantation, it is generally considered to be poor in patients with myeloid sarcoma. The aim of this review is to indicate the potential therapeutic effects of high-dose glucocorticoid treatment which induce differentiation and apoptosis of myeloid leukemic cells, as a new treatment approach for patients with myeloid sarcoma. We have shown that short-course (3 to7 days) high-dose methylprednisolone treatment that might also induce differentiation and apoptosis of leukemic cells in the extramedullary sites resulted in dramatic decreases in the size of myeloid sarcoma in children with or without marrow infiltration. From the results of our long-term clinical studies, we suggest that to use short- course high-dose glucocorticoids combined with intensive chemotherapy protocol would be a promising treatment strategy for patients with myeloid sarcoma. However, in further studies, the prognostic significance of different localization of myeloid sarcoma and the long term effect of the addition of highdose glucocorticoid to intensive AML chemotherapy protocols should be explored in larger series.